Novel virally targeted therapies of EBV-associated tumors

Current Cancer Drug Targets

Volumn 8, Issue 7, 2008, Pages 581-596

  De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; AZACITIDINE; CD4 ANTIGEN; CD8 ANTIGEN; CELECOXIB; CIDOFOVIR; DENDRITIC CELL VACCINE; DEOXYCYTIDINE; DEXAMETHASONE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN 1; FOSCARNET; GANCICLOVIR; GENE PRODUCT; HYDROXYUREA; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; PROTEIN BRLF1; RECOMBINANT GLYCOPROTEIN GP 350; TUMOR VACCINE; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS ANTIGEN; ZEBULARINE; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; BURKITT LYMPHOMA; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EPIGENETICS; EPSTEIN BARR VIRUS; EX VIVO STUDY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHUMAN; PHENOTYPE; REGULATORY MECHANISM; REVIEW; T CELL LYMPHOMA; VIRAL GENE THERAPY; VIRUS GENE; VIRUS REPLICATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METHODOLOGY; NEOPLASM; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 55449095467     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786241069     Document Type: Review

References (122)

1. Cohen, J. I. Epstein-Barr virus infection. N. Engl. J. Med. 2000, 343, 481-492.
2. Thompson, P. T.; Kurzrock, R. Epstein-Barr virus and cancer. Clin. Cancer Res. 2004, 10, 803-821.
3. Young, L. S.; Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4, 757-768.
4. Klein, E.; Kis, L. L.; Klein, G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007, 26, 1297-1305.
5. Tao, Q.; Young, L. S.; Woodman, C. B.; Murray, P. G. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front. Biosci. 2006, 11, 2672-2713.
6. Baumforth, K. R. N.; Young, L. S.; Flavell, K. J.; Constandinou, C.; Murray, P. G. The Epstein-Barr virus and its association with human cancers. Mol. Pathol. 1999, 52, 307-322.
7. Khanna, R.; Moss, D.; Ghandi, M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat. Clin. Pract. Oncol. 2005, 2, 138-149.
8. Wei, W. I.; Sham, J. S. Nasopharyngeal carcinoma. Lancet 2005, 365, 2041-2054.
9. Gandhi, M. K.; Tellam, J. T.; Khanna, R. Epstein-Barr virus-associated Hodgkin's lymphoma. Br. J. Haematol. 2004, 125, 267-281.
10. Chan, A. T.; Teo, P. M.; Huang, D. P. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin. Oncol. 2004, 31, 794-801.
11. Forastiere, A.; Koch, W.; Trotti, A.; Sidransky, D. Head and neck cancer. N. Engl. J. Med. 2001, 346, 1890-1900.
12. Wang, B.; Lu, J. J.; Ma, X.; Guo, Y.; Hong, X.; Li, J. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk. Lymphoma 2007, 48, 396-402.
13. Jones, R. J.; Seaman, W. T.; Feng, W. H.; Barlow, E.; Dickerson, S.; Delecluse, H. J.; Kenney, S. C. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int. J. Cancer 2007, 121, 1274-1281.
14. Hong, G. K.; Gulley, M. L.; Feng, W. H.; Delecluse, H. J.; Holley-Guthrie, E.; Kenney, S. C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 2005, 79, 13993-14003.
15. Young, L. S.; Murray, P. G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003, 33, 5108-5121.
16. Wang, D.; Liebowitz, D.; Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43, 831-840.
17. Zheng, H.; Li, L. L.; Hu, D. S.; Deng, X. Y.; Cao, Y. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol. Immunol. 2007, 4, 185-196.
18. Scholle, F.; Bendt, K. M.; Raab-Traub, N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 2000, 74, 10681-10689.
19. Leao, M.; Anderton, E.; Wade, M.; Meekings, K.; Allday, M. J. Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J. Virol. 2006, 81, 248-260.
20. Griffiths, P. D. Interactions between viral and human genes. Rev. Med. Virol. 2002, 12, 197-199.
21. Hutt-Fletcher, L. M. Epstein-Barr virus entry. J. Virol. 2007, 81, 7825-7832.
22. Robertson, K. D. DNA methylation and human disease. Nat. Rev. Genetics 2005, 6, 597-610.
23. Jones P.A. Overview of cancer epigenetics. Semin. Hematol. 2005, 42, s3-s8.
24. Kintner, C.; Sugden, B. Conservation and progressive methylation of Epstein-Barr viral DNA sequences intransformed cells. J. Virol. 1981, 38, 305-316.
25. Tao, Q.; Robertson, K. D. Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin. Immunol. 2003, 109, 53-63.
26. Allday, M. J.; Kundu, D.; Finerty, S.; Griffin, B. E. CpG methylation of viral DNA in EBV-associated tumours. Int. J. Cancer 1990, 45, 1125-1130.
27. Hutchings, I. A.; Tierney, R. J.; Kelly, G. L.; Stylianou, J.; Rickinson, A. B.; Bell, A. I. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J. Virol. 2006, 80, 10700-10711.
28. Werner, M.; Ernberg, I.; Zou, J.; Almqvist, J.; Aurell, E. Epstein-Barr virus latency switch in human B-cells: a physico-chemical model. BMC Syst. Biol. 2007, 31, 40.
29. Schaefer, B. C.; Strominger, J. L.; Speck, S. H. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol. Cell Biol. 1997, 17, 364-377.
30. Zetterberg, H.; Stenglein, M.; jansson, A.; Ricksten, A.; Rymo, L. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. J. Gen. Virol. 1999, 80, 457-466.
31. Tsai, C. N.; Liu, S. T.; Chang, Y. S. Identification of a novel promoter located within the Bam HI Q region of the Epstein-Barr virus genome for the EBNA 1 gene. DNA Cell Biol. 1995, 14, 767-776.
32. Ambinder, R. F.; Robertson, K. D.; Tao, Q. DNA methylation and the Epstein-Barr virus. Semin. Cancer Biol. 1999, 9, 369-375.
33. Tao, Q.; Robertson, K. D.; Manns, A.; Hildesheim, A.; Ambinder, R. F. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998, 15, 1373-1381.
34. Tao, Q.; Swinnen, L. J.; Yang, J.; Srivastava, G.; Robertson, K. D.; Ambinder, R. F. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am. J. Pathol. 1999, 155, 619-625.
35. Straathof, K. C.; Bollard, C. M.; Rooney, C. M.; Heslop, H. E. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003, 8, 83-98.
36. Masmoudi, A.; Toumi, N.; Khanfir, A.; Kallel-Slimi, L.; Daoud, J.; Karray, H.; Frikha, M. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat. Rev. 2007, 33, 499-505.
37. Callan, M. F. The immune response to Epstein-Barr virus. Microbes Infect. 2004, 6, 937-945.
38. Landais, E.; Saulquin, X.; Houssaint, E. The human T cell immune response to Epstein-Barr virus. Int. J. Dev. Biol. 2005, 49, 285-292.
39. Hislop, A. D.; Taylor, G. S.; Sauce, D.; Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25, 587-617.
40. Li, J.; Zeng, X. H.; Mo, H. Y.; Rolen, U.; Gao, Y. F.; Zhang, X. S.; Chen, Q. Y.; Zhang, L.; Zeng, M. S.; Li, M. Z.; Huang, W. L.; Zeng, Y. X.; Masucci, M. G. Functional inactivation of EBV-specific T-lymphocytes in nasopharingeal carcinoma: implications for tumor immunotherapy. PLoS ONE 2007, 7, e1122.
41. Zanussi, S.; Vaccher, E.; Caffau, C.; Pratesi, C.; Crepaldi, C.; Botrolin, M. T.; Tedeschi, R.; Politi, D.; Barzan, L.; Tirelli, U.; De Paoli, P. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol. Immunother. 2003, 52, 28-32.
42. Precopio, M. L.; Sullivan, J. L.; Willard, C.; Somasundaran, M.; Luziriaga, K. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. 2003, 170, 2590-2598.
43. Levitskaya, J.; Coram, M.; Levitsky, V.; Imreh, S.; Steigerwald-Mullen, P. M.; Klein, G.; Kurilla, M. G.; Masucci, N. G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995, 375, 685-688.
44. Tan, L. C.; Gudgeon, N.; Annels, N. E.; Hansasuta, P.; O'Callaghan, C. A.; Rowland-Jones, S.; McMichael, A. J.; Rickinson, A. B.; Callan, M. F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 1999, 162, 1827-1835.
45. Jurgens, L. A.; Khanna, R.; Weber, J.; Orentas, R. J. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J. Clin. Immunol. 2006, 26, 22-32.
46. Frisan, T.; Sjoberg, J.; Dlocetti, R.; Boiocchi, M.; De Re, V.; Carbone, A.; Brautbar, C.; Battat, S.; Biberfeld, P.; Eckman, M. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995, 86, 1493-1501.
47. Paludan, C.; Munz, C. CD4+ T cells respones in the immune control against latent infection by Epstein-Barr virus. Curr. Mol. Med. 2003, 3, 341-347.
48. Adhikary, D.; Behrends, U.; Boerschmann, H.; Pfunder, A.; Burdach, S.; Moosmann, A.; Witter, K.; Bornkamm, G. W.; Mautner, J. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE 2007, 2, e583.
49. Haigh, T. A.; Lin, X.; Jia, H.; Hui, E. P.; Chan, A. T.; Rickinson, A. B.; Taylor, G. S. EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J. Immunol. 2008, 180, 1643-1654.
50. Munz, C. Epstein-Barr virus nuclear antigen 1: from immunological invisible to a promising T cell target. J. Exp. Med. 2004, 199, 1301-1304.
51. Heller, K. N.; Gurer C.; Munz, C. Virus-specific CD4+ T cells: ready for direct attack. J. Exp. Med. 2006, 203, 805-808.
52. Nikiforow, S.; Bottomly, K.; Miller, G.; Munz, C. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 2003, 77, 12088-12104.
53. Haque, T.; Wilkie, G. M.; Jones, M. M.; Higgins, C. D.; Urquhart, G.; Wingate, P.; Burns, D.; McAulay, K.; Turner, M.; Bellamy, C.; Amlot, P. L.; Kelly, D.; MacGilchrist, A.; Gandhi, M. K.; Swerdlow, A. J.; Crawford, D. H. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110, 1123-1131.
54. Marincola, F. M.; Jaffee, E. M.; Hicklin, D. J.; Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000, 74, 181-273.
55. de Campos-Lima, P. O.; Levitskaya, J.; Frisan, T.; Masucci, M. G. Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis. Semin. Virol. 1996, 7, 75-82.
56. Dolcetti, R.; Masucci, M. G. Epstein-Barr virus: induction and control of cell transformation. J. Cell Physiol. 2003, 196, 207-218.
57. Ogino, T.; Moriai, S.; Ishida, Y.; Ishii, H.; Katayama, A.; Miyokawa, N.; Harabuchi, Y.; Ferrone, S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int. J. Cancer 2007, 120, 2401-2410.
58. Murray, R. J.; Kurilla, M. G.; Brooks, J. M.; Rowe, M.; Kieff, E.; Rickinson, A. B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 1992, 176, 157-168.
59. Vicari, A. P.; Trinchieri, G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol. Rev. 2004, 202, 223-236.
60. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784.
61. Kim, T. Y.; Bang, Y. J.; Robertson, K. D. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006, 1, 14-23.
62. Macsween, K. F.; Crawford, D. H. Epstein-Barr virus-recent advances. Lancet Infect. Dis. 2003, 3, 131-140.
63. De Paoli, P.; Pratesi, C.; Bortolin, M. T. The Epstein-Barr virus DNA levels as a tumor marker in EBV-associated cancers. J. Cancer Res. Clin. Oncol. 2007, 133, 809-815.
64. Yustein, J. T.; Dang, C. V. Biology and treatment of Burkitt's lymphoma. Curr. Opin. Hematol. 2007, 14, 375-381.
65. Brady, G.; MacArthur, G. J.; Farrell, P. J. Epstein-Barr virus and Burkitt lyphoma. J. Clin. Pathol. 2007, 60, 1397-1402.
66. Thomas, D. A.; Faderl, S.; O'Brien, S.; Bueso-Ramos, C.; Cortes, J.; Garcia-Manero, G.; Giles, F. J.; Verstovsek, S.; Wierda, W. G.; Pierce, S. A.; Shan, J.; Brandt, M.; Hagemeister, F. B.; Keating, M. J.; Cabanillas, F.; Kantarjian, H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106, 1569-1580.
67. Hasserjian, R. P.; Harris, N. L. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am. J. Clin. Pathol. 2007, 127, 860-868.
68. Hsieh, P. P.; Tung, C. L.; Chan, A. B.; Liao, J. B.; Wang, J. S.; Tseng, H. H.; Su, H. H.; Chang, K. C.; Chang, C. C. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am. J. Clin. Pathol. 2007, 128, 579-584.
69. Oshimi, K. Progress in understanding and managing natural killer-cell malignancies. Br. J. Hematol. 2007, 139, 532-544.
70. Kim, H. S.; Kim, J. S.; Kim, J. S.; Park, J. T.; Lee, M. C.; Juhng, S. W.; Cho, J. H.; Park, C. S. The association between CD99 and LMP-1 expression in nasopharyngeal carcinoma. Exp. Oncol. 2006, 28, 40-43.
71. Keegan, T. H.; Glaser, S. L.; Clarke, C. A.; Gulley, M. L.; Craig, F. E.; Digiuseppe, J. A.; Dorfman, R. F.; Mann, R. B.; Ambinder, R. F. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J. Clin. Oncol. 2005, 23, 7604-7613.
72. Nichols, K. E.; Ma, C. S.; Cannons, J. L.; Schwartzberg, P. L.; Tangye, S. G. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol. Rev. 2005, 203, 180-199.
73. Taylor, A. L.; Marcus, R.; Bradley, J. A. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit. Rev. Oncol. Hematol. 2005, 56, 155-167.
74. Yarchoan, R.; Tosato, G.; Little, R. F. Therapy insight: AIDS-related malignancies in the influence of antiviral therapy on pathogenesis and maangement. Nat. Clin. Pract. Oncol. 2005, 2, 406-415.
75. Gershburg, E.; Pagano, J. S. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 2005, 56, 277-281.
76. Abdulkarim, B.; Bourhis, J. Antiviral approaches for cancers related to Epstein-Barr virus and human papillomavirus. Lancet Oncol. 2001, 2, 622-630.
77. Westphal, E. M.; Blackstock, W.; Feng, W.; Israel, B.; Kenney, S. C. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 2000, 60, 5781-5788.
78. Feng, W. H.; Kenney, S. C. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006, 66, 8762-8769.
79. Daibata, M.; Bandobashi, K.; Kuroda, M.; Imai, S.; Miyoshi, I.; Taguchi, H. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. J. Virol. 2005, 79, 5875-5879.
80. Slobod, K. S.; Taylor, G. H.; Sandlund, J. T.; Furth, P.; Helton, K. J.; Sixbey, J. W. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000, 356, 1493-1494.
81. Dhar, S. K.; Yoshida, K.; Khaira, P.; Chaudhuri, B.; Wohlschlegel, J. A.; Leffak, M.; Yates, J.; Dutta, A. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001, 106, 287-196.
82. Kenney, J. L.; Guinness, M. E.; Curiel, T.; Lacy, J. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92, 1721-1727.
83. Dallas, A.; Vlassov, A. V. RNAi: a novel antisense technology and its therapeutic potential. Med. Sci. Monit. 2006, 12, RA67-RA74.
84. Mei, Y. P.; Zhou, J. M.; Wang, Y.; Huang, H.; Deng, R.; Feng, G. K.; Zeng, Y. X.; Zhu, X. F. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007, 6, 1379-1385.
85. Israel, B. F.; Kenney, S. C. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003, 22, 5122-5130.
86. Feng, W.; Westphal, E. M.; Mauser, A.; Raab-Traub, N.; Gulley, M.; Busson, P.; Kenney, S. C. Use of adenovirus vectors expressing Epstein-Barr Virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J. Virol. 2002, 76, 10951-10959.
87. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
88. Suzuki, H.; Gabrielson, E.; Chen, W.; Anbazhagan, R.; Van Engeland, M.; Weijnberg, M. P.; Herman, J. G.; Baylin, S. B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 2002, 31, 141-149.
89. Plimack, E. R.; Stewart D.J.; Issa, J. J. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J. Clin. Oncol. 2007, 25, 4519-4521.
90. Camphausen, K.; Tofilon, P. J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 2007, 25, 4051-4056.
91. Abele, R.; Clavel, M.; Dodion, P.; Bruntsch, U.; Gundersen, S.; Smyth, J.; Renard, J.; van Glabbeke, M.; Pinedo, H. M. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. 1987, 23, 1921-1924.
92. van Groeningen, C. J.; Leyva, A.; O'Brien, A. M. P.; Gall, H. E.; Pinedo, H. M. Phase I and pharmacokinetic study od 5-Aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986, 46, 4831-4836.
93. Rao, S. P.; Rechsteiner, M. P.; Berger, C.; Sigrist, J. A.; Nadal, D.; Bernasconi, M. Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol. Cancer 2007, 6, 3.
94. Chan, A. T.; Tao, Q.; Robertson, K. D.; Flinn, I. W.; Mann, R. B.; Klencke, B.; Kwan, W. H.; Leung, T. W.; Johnson, P. J.; Ambinder, R. F. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J. Clin. Oncol. 2004, 22, 1373-1381.
95. June, C. H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 2007, 117, 1204-1212.
96. Chua, D.; Huang, J.; Zheng, B.; Lau, S. Y.; Luk, W.; Kwong, D. L. W.; Sham, J. S. T.; Moss, D.; Yuen, K. Y.; Im, S. W. K.; Ng, M. H. Adoptive transfer of autologous Epstein-Barr Virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer 2001, 94, 73-80.
97. Comoli, P.; Pedrazzoli, P.; Maccario, R.; Basso, S.; Carminati, O.; Labirio, M.; Schiavo, R.; Secondino, S.; Frasson, C.; Perotti, C.; Moroni, M.; Locatelli, F.; Siena, S. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr Viris-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 2005, 23, 8942-8949.
98. Clinical Trials.gov. A service of the US National Institute of Health. http://clinicaltrials. gov 2008.
99. Comoli, P.; De Palma, R.; Siena, S.; Nocera, A.; Basso, S.; Del Galdo, F.; Schiavo, R.; Carminati, O.; Tagliamacco, A.; Abbate, G. F.; Locatelli, F.; Maccario, R.; Pedrazzoli, P. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. 2004, 15, 113-117.
100. Roskrow, M. A.; Suzuki, N.; Gan, Y. J.; Sixbey, J. W.; Ng, C. Y.; Kimbrough, S.; Hudson, M.; Brenner, M. K.; Heslop, H. E.; Rooney, C. M. Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91, 2925-2934.
101. Bollard, C. M.; Aguilar, L.; Straathof, K. C.; Gahn, B.; Huls, M. H.; Rousseau, A.; Sixbey, J. W.; Gresik, M. V.; Carrum, G.; Hudson, M.; Dilloo, D.; Gee, A.; Brenner, M. K.; Rooney, C. M.; Heslop, H. E. Cytotoxic T lymphocyte therapy for Epstein-Barr Virus + Hodgkin's disease. J. Exp. Med. 2004, 200, 1623-1633.
102. Lucas, K. G.; Salzman, D.; Garcia, A.; Sun, Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004, 100, 1892-1901.
103. Savoldo, B.; Rooney, C. M.; Di Stasi, A.; Abken, H.; Hombach, A.; Foster, A. E.; Zhang, L.; Heslop, H. E. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007, 110, 2620-2630.
104. Comoli, P.; Basso, S.; Zecca, M.; Pagliara, D.; Baldanti, F.; Bernardo, M. E.; Barberi, W.; Moretta, A.; Labirio, M.; Paulli, M.; Furione, M.; Maccario, R.; Locatelli, F. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 2007, 7, 1648-1655.
105. Biocca, S.; Cattaneo, A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol. 1995, 5, 248-252.
106. Williams, B. R.; Zhu, Z. Intrabody-based approaches to cancer therapy: status and prospects. Curr. Med. Chem. 2006, 13, 1473-1480.
107. Doorbar, J.; Griffin, H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin. Biol. Ther. 2007, 7, 677-689.
108. Piché, A.; Kasono, K.; Johanning, F.; Curiel, T. J.; Curiel, D. T. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther. 1998, 5, 1171-1179.
109. Moutschen, M.; Léonard, P.; Sokal, E.; Smets, F.; Haumont, M.; Mazzu, P.; Denamur, F.; Peeters, P.; Dubin, G.; Denis, M. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007, 25, 4697-4705.
110. Taylor, G. S.; Haigh, T. A.; Gudgeon, N. H.; Phelps, R. J.; Lee, S. P.; Steven, N. M.; Rickinson, A. B. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 2004, 78, 768-778.
111. Wang, F. "T"-ing off on nasopharynx cancer. Blood 2005, 105, 1841-1842.
112. Lin, C. L.; Lo, W. F.; Lee, T. H.; Ren, Y.; Hwang, S. L.; Cheng, Y. F.; Chen, C. L.; Chang, Y. S. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002, 62, 6952-6958.
113. Duraiswamy, J.; Sherritt, M.; Thomson, S.; Tellam, J.; Cooper, L.; Connolly, G.; Bharadwaj, M.; Khanna, R. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003, 101, 3150-3156.
114. Thomson, S. A.; Duraiswamy, J.; Moss, D. Treatment of Epstein-Barr Virus-associated diseases (WO/2007/065215). www. wipo. int 2007.
115. Depil, S.; Moralès O.; Castelli, F. A.; François, V.; Georges, B.; Dufossé, F.; Morschhauser, F.; Hammer, J.; Maillère, B.; Auriault, C.; Pancré, V. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J. Immunother. 2007, 30, 215-226.
116. Tacken, P. J.; de Vries, I. J.; Torensma, R.; Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7, 790-802.
117. Vulink, A.; Radford, K. J.; Melief, C.; Hart, D. N. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 2008, 99, 363-407.
118. Schönthal, A. H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 2007, 97, 1465-1468.
119. Doubrovin, M. M.; Doubrovina, E. S.; Zanzonico, P.; Sadelain, M.; Larson, S. M.; O'Reilly, R. J. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res. 2007, 67, 11959-11969.
120. Gattinoni, L.; Powell, D. J.; Rosenberg, S. A., Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6, 383-393.
121. Martorelli, D.; Houali, K.; Caggiari, L.; Vaccher, E.; Barman, L.; Franchin, G.; Gloghini, A.; Pavan, A.; Da Ponte, A.; De Re, V.; Carbone, A.; Ooka, T.; De Paoli, P.; Dolcetti, R. Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasophayngeal carcinoma:bases for improved immunotherapy. Int. J. Cancer 2008, 123, 1100-1107.
122. Seder, R. A.; Darrah, P. A.; Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8, 247-258.